It is made available under a CC-BY-NC-ND 4.0 International license .

1 2 3

4

In-concert immune dynamics during natural influenza virus infection and recovery in acute hospitalized patients

Thi H.O. Nguyen¹, Marios Koutsakos¹, Carolien E. van de Sandt^{1,2}, Jeremy Chase Crawford³,
Liyen Loh¹, Sneha Sant¹, Ludivine Grzelak⁴, Emma K. Allen³, Tim Brahm³, E. Bridie
Clemens¹, Maria Auladell¹, Luca Hensen¹, Zhongfang Wang¹, Simone Nüssing¹, Xiaoxiao Jia¹,
Patrick Günther¹, Adam K. Wheatley¹, Stephen J. Kent^{1,5,6}, Malet Aban⁷, Yi-Mo Deng⁷, Karen
L. Laurie⁷, Aeron C. Hurt⁷, Stephanie Gras^{8,9}, Jamie Rossjohn⁸⁻¹⁰, Jane Crowe¹¹, Jianqing Xu¹²,
David Jackson¹, Lorena E. Brown¹, Nicole La Gruta⁸, Weisan Chen¹³, Peter C. Doherty¹,
Stephen J. Turner¹⁴, Tom C. Kotsimbos^{15,16}, Paul G. Thomas³, Allen C. Cheng^{17,18*#} and

- 13 Katherine Kedzierska^{1*#}
- 14

15 Affiliations

- ¹Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty
 Institute for Infection and Immunity, Parkville 3010, Victoria, Australia.
- ¹⁸²Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam
- 19 UMC, University of Amsterdam, 1066CX, Amsterdam, Netherlands.
- ³Department of Immunology, St Jude Children's Research Hospital, Memphis 38105,
 Tennessee, USA.
- ⁴Biology Department, École Normale Supérieure Paris-Saclay, Université Paris-Saclay Cachan
 94230, France.
- ²⁴ ⁵Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and
- 25 Central Clinical School, Monash University, Melbourne 3004, Victoria, Australia.
- ⁶ARC Centre for Excellence in Convergent Bio-Nano Science and Technology, University of
- 27 Melbourne, Parkville 3010, Victoria, Australia.
- ²⁸ ⁷World Health Organisation (WHO) Collaborating Centre for Reference and Research on
- Influenza, at The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Victoria,Australia.
- ⁸Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash
 University, Clayton 3800, Victoria, Australia.
- ³³ ⁹Australian Research Council Centre of Excellence for Advanced Molecular Imaging, Monash
- 34 University, Clayton 3800, Victoria, Australia.
- ¹⁰Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park,
- 36 Cardiff CF14 4XN, United Kingdom.
- 37 ¹¹Deepdene Surgery, Deepdene 3103, Victoria, Australia.
- 38 ¹²Shanghai Public Health Clinical Centre and Institutes of Biomedical Sciences, Key Laboratory
- of Medical Molecular Virology of Ministry of Education/Health, Shanghai Medical College,
 Fudan University, Shanghai 201508, China.
- ¹³Department of Biochemistry and Genetics, La Trobe Institute of Molecular Science, La Trobe
 University, Bundoora 3084, Victoria, Australia.
- 43 ¹⁴Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton
- 44 3800, Victoria, Australia.
- ¹⁵Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital,
 Melbourne 3004, Victoria, Australia.
- 47 ¹⁶Department of Medicine, Monash University, Central Clinical School, The Alfred Hospital
- 48 Melbourne 3004, Victoria, Australia.
- ¹⁷School of Public Health and Preventive Medicine, Monash University, Melbourne 3004,
 Victoria, Australia.
- ¹⁸Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, Melbourne 3004,
 Victoria, Australia.
- 53 KLL is currently at Seqirus, Parkville 3052, Victoria, Australia.
- 54 ^{*}These authors contributed equally.
- [#]Corresponding authors: <u>kkedz@unimelb.edu.au</u>; allen.cheng@monash.edu.
- 56 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

It is made available under a CC-BY-NC-ND 4.0 International license .

57 Abstract

58 We report in-concert dynamics of 18 key immune parameters, related to clinical, genetic and 59 virological factors, in patients hospitalized with influenza across different severity levels. Influenza disease was associated with correlated increases in IL6/IL-8/MIP-1 α/β cytokines and 60 61 lower antibody responses. Robust activation of circulating T follicular helper cells (cTfhs) 62 correlated with peak antibody-secreting cells (ASC) and influenza heamaglutinin-specific 63 memory B-cell numbers, which phenotypically differed from vaccination-induced B-cell responses. Influenza-specific CD8⁺/CD4⁺ T-cells increased early in disease and remained 64 65 activated during patient recovery. Here, we describe the broadest to-date immune cellular 66 networks underlying recovery from influenza infection, highly relevant to other infectious 67 diseases.

- 68
- 69

70 Millions of people are hospitalized with severe influenza disease annually. In 2017, an estimated 9.5 million people globally were hospitalized with influenza virus lower respiratory tract 71 72 infections, for a total of 81.5 million days¹. Moreover, an estimated 243,000-645,000 of seasonal influenza-associated respiratory deaths occur annually². Although seasonal influenza virus 73 74 infections can cause debilitating illness leading to hospitalization and death³, viral, host and 75 immune factors determining the disease severity are unclear, as are the precise mechanisms of 76 why some individuals present with a mild 'asymptomatic' infection, while others, including 77 previously healthy or vaccinated individuals, succumb to severe viral pneumonia and fatal 78 influenza disease. Increased susceptibility to influenza virus infection and exacerbation of 79 disease severity can reflect an overactivation of the innate immune system, leading to 80 hypercytokinemia, alveolar oedema and pulmonary complications, and/or impaired humoral and 81 cellular immunity, delaying the recovery phase. While neutralizing antibodies can reduce 82 disease transmission and viral load, the current vaccination regimens targeting antibody 83 responses⁴ are often short-lived and directed against specific influenza strains, thus not protective against unpredicted influenza viruses. 84

85 Based on human studies of natural and experimental influenza virus infection, it is wellestablished that in the absence of neutralizing antibodies, pre-existing memory CD8⁺ T cells and 86 CD4⁺ T cells can reduce disease severity⁵⁻¹⁴. Published evidence also associates genetic host 87 88 factors, such as specific HLA types and interferon-induced transmembrane protein 3 (IFITM3) single-nucleotide polymorphisms (SNPs) with clinically poor outcomes¹⁵⁻¹⁸. The IFITM3 89 90 rs12252-C/C genotype along with early detection of inflammatory mediators IL-6, IL-8, IL-10 91 and MIP-1 β measured in the blood within 48 hours of hospital admission, were associated with 92 fatal disease outcomes in our 2013 study of hospitalized H7N9-infected patients in China (n=18 93 patients, 12 recovered, 6 died)¹⁸. In contrast, recovery from severe H7N9 infection was associated with lower cytokine levels and prominent $CD8^+$ T cell responses¹⁸. Inflammatory 94 95 serum cytokines IL-6 and IL-8 have also been linked to severe seasonal and pandemic influenza virus infections in hospitalized adult patients¹⁹ and predicted hospitalization in a household 96 97 cohort of naturally-infected individuals, including infants, children and adults²⁰. In critically-ill 98 children, higher levels of blood cytokines (IL-6, IL-8, IP-10, GM-CSF, MCP-1, and MIP-1 α) 99 measured within 72 hours of ICU admission correlated with fatal influenza virus infection²¹.

100 There is scant data on the main drivers of severe influenza resulting in hospitalization or death^{22,23}. Previous studies of influenza-infected patient cohorts mainly focused on a very select 101 number of immunological parameters, with only three studies combining innate 102 (cytokines/monocytes/NK cells) and adaptive T cell immunity^{12,24,25}, and two other studies 103 incorporating innate immunity, T cell immunity and antibody responses^{10,26}. The limited number 104 105 of parameters measured is often due to a difficulty in obtaining longitudinal samples from 106 acutely-infected patients combined with the amount of biological material required per assay. Only one other study, the SHIVERS report²⁶ analysed convalescent samples 2 weeks post-107 enrolment (along with one acute sample) and showed prolonged immune activation of innate 108 109 and adaptive cellular responses in hospitalized patients compared to non-hospitalized patients.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 110 Thus, there is a clear deficiency in our understanding of the specific interplay between genetics,
- 111 innate and adaptive immune responses driving recovery from acute viral pneumonia.

112 Here, we utilized longitudinal samples obtained from patients hospitalized with acute 113 influenza disease to elucidate how innate and adaptive immune responses work in concert to 114 resolve influenza disease. We report, at a very high level of resolution, the overall breadth and 115 kinetics of 18 key immune parameters: the antiviral/inflammatory cytokines and chemokines, 116 hemagglutinin (HA)-directed antibodies, HA-probe-specific B cells, antibody-secreting cells 117 (ASCs), circulatory CD4⁺ T follicular helper (cTfh) cells, influenza peptide/MHC-specific CD8⁺ 118 and CD4⁺ T cells, IFN- γ -producing CD8⁺ T cells, CD4⁺ T cells, Natural Killer (NK) cells, 119 Mucosal-associated invariant T (MAIT) and γδ T cells, and granzymes A, B, K, M and perforin 120 expression in CD8⁺, CD4⁺, NK and MAIT cells. This comprehensive panel of immune 121 parameters, combined with host genetic factors and patient clinical data, enabled a detailed 122 dissection of human factors driving susceptibility, severity and recovery in patients hospitalized 123 with seasonal influenza viruses, highly relevant to other infectious diseases, especially newly-124 emerging respiratory infections.

- 125
- 126

127 **Results**

128 Patient DISI cohort

129 We recruited 64 patients admitted to the Alfred Hospital (Prahran, Australia) between 2014-130 2017 into our "Dissection of Influenza-Specific Immunity" (DISI) cohort. The inclusion criteria 131 for the DISI study included hospital admission of consenting adult patients with influenza-like 132 illness (ILI). The longitudinal study involved serial blood and nasal swab samples collected 133 from influenza-PCR-positive patients (Flu+, n=44) within 1-2 days of hospital admission to 134 discharge and follow-up blood samples ~30 days later, allowing analyses of the recovery phase 135 (Fig. 1a). Patients who were influenza-PCR-negative (Flu-, n=20) were included as ILI-matched 136 controls. The DISI cohort included one patient #11 who became infected with H3N2 while in 137 hospital with AML, and died 34 days later from febrile neutropenia. We also had one death in 138 the control group, patient #28 who was PCR-negative at admission, but subsequently became 139 IBV-PCR-positive while in hospital and died 61 days later in ICU. The remaining cohort was 140 admitted to the Respiratory/General Ward with one case patient #62 requiring 1 day in ICU. 53 141 patients presented with ILI, while 6 cases and 1 control patient presented with pneumonia 142 (Supplementary Tables 1 and 2).

143 We successfully recalled 80% (35/44) of Flu+ patients at a median of 41 days after 144 disease onset and 75% of our Flu- patients (15/20, median 39 days). Overall, Flu+ patients were 145 predominantly (55%) infected with the H3N2 influenza A virus (IAV) subtype (Fig. 1b and 146 Supplementary Table 1), followed by the co-circulating IAV 2009 pandemic H1N1 (pH1N1)-147 like strain (16%) and two co-circulating influenza B virus (IBV) strains (Phuket/3073/2013 148 (9%) and Brisbane/60/2008 (7%)), representing the dominant strains for each year in Australia. 149 IAV-infected patients (median 58 yrs, n=34) were significantly older than IBV-infected (45 yrs, 150 n=10) and Flu- patients (47 yrs, n=20) (Fig. 1c). Apart from age, patient demographics in Flu+ and Flu- groups were well-matched, with 86% and 70%, respectively, having one or more high-151 152 risk conditions for severe influenza disease. Both groups had a median of 4 days in hospital 153 (Supplementary Tables 1-2). Time in hospital was significantly lower than that for more severely-ill H7N9 cohort¹⁸ with a median 14 days for recovery (n=12, p<0.0001) and a median 154 155 of 33 days for those who died (n=6, p=0.0239) (Fig. 1d). The lower hospital burden reflects the 156 lower severity of seasonal influenza compared to avian A/H7N9 disease.

157

158 Risk HLA class-I and IFITM3-SNPs do not contribute to disease severity in hospital settings

To determine whether the risk HLA class-I and IFITM3-SNPs genetic factors contributed to influenza disease severity in hospitalized patients, we compared HLA type and IFITM3 SNP alleles between Flu+ and Flu- patients. HLA types (**Supplementary Table 2**) were grouped according to "universal" or "risk" alleles based on studies describing HLA-A*02:01/03:01 and

163 HLA-B*08:01/18:01/27:05/57:01 molecules binding universally conserved influenza peptides²⁷,

It is made available under a CC-BY-NC-ND 4.0 International license .

versus HLA-A*24:02/68:01 types positively correlating with pH1N1 mortality¹⁵ and 164 morbidity¹⁶. Given that our cohort was mainly Caucasian (82% Flu+, 95% Flu-, 165 166 Supplementary Table 1), the frequencies of universal and risk alleles were comparable 167 between two groups (Fig. 1e). Similarly, for IFITM3 SNP analyses, the non-risk rs12252-T/T 168 homozygous allele was observed in 91% of Flu+ patients (remaining were C/T heterozygous) 169 and 100% of Flu- patients, whereas the risk C/C homozygous allele was absent (Fig. 1f). The 170 rs34481144 SNP showed a higher frequency of the A/G-heterozygous allele for both groups 171 (41% and 50%, respectively), with equal or similar proportions of the risk A/A and non-risk 172 G/G homozygous alleles (Fig. 1g). Further analyses of Flu+ patients with the risk A/A 173 rs34481144 SNP versus Flu+ patients with A/G-heterozygous allele and non-risk G/G 174 homozygous alleles showed no differences in disease severity in hospital settings, as measured 175 by sequential (sepsis-related) organ failure assessment (SOFA) scores²⁸ (Fig. 1h).

176

177 Highly correlated cytokines cluster together during influenza virus infection

178 Hypercytokinemia of early inflammatory mediators (IL-6, IL-8, IL-10, MCP-1, MIP-1 α and MIP-1B) have been associated with an increase in disease severity causing death in a number of 179 hospitalized cohorts¹⁸⁻²¹. Pro-inflammatory cytokines and chemokines measured in the blood of 180 181 acute representative Flu+ patients showed increased cytokine levels, particularly IL-6 and IL-8, 182 between mild and moderate patients as defined by lower (0-1) or higher (2-6) SOFA scores, 183 respectively, and in the more severe patient requiring ICU support (Fig. 1i). Heightened IL-6 levels were also associated with the more severe 2013 H7N9-infected patients (Fig. 1i)¹⁸. After 184 185 adjusting for age and the sampling time after days of disease onset, IL-6, IL-8, MIP-1 α and 186 MIP-1 β were significantly, strongly positively correlated with each other early after infection at 187 V1 timepoint. This inter-correlated cytokine cluster was still strongly present at convalescence, 188 with less significant correlations with other cytokines/chemokines (Fig. 1j). Therefore, our data 189 support previous reports that IL-6, IL-8, MIP1 α and MIP-1 β serve as biomarkers for severe 190 influeza disease.

191

192 Antibody responses increase in magnitude and breadth at convalescence

193 The annual influenza vaccine is provided for free for high-risk groups under the National 194 Immunisation Program. Despite the high proportion of Flu+ patients in this cohort being defined 195 as high-risk due to pre-exisiting comorbidities (86%), only 48% of these patients were 196 vaccinated against influenza prior to infection, compared to 65% of Flu- patients 197 (Supplementary Table 1). There was rapid antigenic drifting of the H3N2 viruses between 198 2014-2017, with more annual updates of the H3-HA vaccine component compared to the less 199 variable H1-HA and B-HA components (Supplementary Table 3). Rapid drift of the H3N2 200 component was evident in the viral HA-sequence analyses of nasal swabs from H3N2-infected 201 patients with sufficient RNA. All 12 H3N2 viruses isolated from patients, including 9 who had 202 been vaccinated, were from a different H3N2 clade when compared to the current H3N2 203 seasonal vaccine strain (Fig. 2a). Conversely, fewer H1-HA and B-HA sequence variations were 204 observed between isolates from the infected patients compared to the WHO reference strains 205 (Supplementary Fig. 1). Interestingly, despite the H3N2 clade-mismatches, all H3N2-infected 206 patients (except one A/unsubtyped patient) generated HA inhibition (HAI) antibody titres of 40 207 and above (equivalent to $\log_2(HAI/10)>2$) against the H3 vaccine strain (same year as infection) 208 at follow-up, compared to 54% at acute timepoints (Fig. 2b), suggesting a boost in strain-209 specific antibodies that may have contributed to the significant increase in vaccine-strain titres 210 (p < 0.0001). However, only marginal increases in antibody titres were observed in H1- and B-211 infected patients at follow-up (Fig. 2b). Geometric mean titres (GMT) were low for all three H1, 212 H3 and B subtypes during acute infection, but their ability to mount antibody responses at 213 follow-up was generally comparable to vaccine-induced responses in a healthy cohort but with 214 greater GMT fold-changes (Fig. 2c,d). As expected, antibody titres were low and remained 215 unchanged in the Flu- group (Fig. 2c,d).

216 Previous exposures to past influenza strains, influenced by age, can affect our immune 217 responses to current influenza virus infections²⁹. To study the breadth of antibody responses,

It is made available under a CC-BY-NC-ND 4.0 International license .

218 HAI antibody landscapes were generated against current and older influenza strains from the last 219 century that the patients may have previously encountered (Supplementary Table 3). Antibody 220 responses to past strains were minimal during acute infection (V1 and V2) (Fig. 2e,f). However, 221 at follow-up, Flu+ patients induced robust antibody responses to older strains from the same 222 subtype that they were infected with, a phenomenon known as back-boosting²⁹, but not against 223 the other subtypes (Fig. 2e,f). Therefore, compared to the Flu- and healthy cohorts, Flu+ 224 patients started with lower antibody titres at hospitalization, perhaps due to lower vaccine 225 coverage, but were able to mount robust and broad antibody responses at convalescence.

226

227 Activation of cTfh, ASCs and influenza-specific memory B cells prior to recovery

Tfh cells are essential for generating high-affinity memory B cells in germinal centers (GCs) and are located in secondary lymphoid organs³⁰. cTfh cells share phenotypic and functional properties to GC Tfh cells, and we and others showed that inactivated influenza vaccination (IIV) induces expansion and PD-1/ICOS-activation of CD4⁺CXCR5⁺CXCR3⁺ cTfh type-1 (cTfh1) cells, which correlated with antibody and CD19⁺CD27⁺⁺CD38⁺⁺ ASC responses^{4,31}.

233 Here, we show for the first time that activated PD-1⁺ICOS⁺ cTfh1 cells emerged within 234 influenza-infected patients in parallel with ASC responses, both peaking between days 7-10 235 after disease onset in both Flu+ and Flu- groups, prior to patients' recovery. cTfh1 cells peaked 236 higher in Flu+ patients compared to Flu- groups, as shown by the separation of the 95% 237 confidence intervals (Fig. 3a-c, Supplementary Fig. 2a). The number of ASCs was 238 significantly higher (~2-8 fold) during acute infection compared to follow-up for both Flu+ and 239 Flu- groups (Fig. 3d). Overall, activated cTfh1 cells were also trending higher at acute 240 compared to follow-up (~2 fold, p=0.0519, Mann-Whitney test, Fig. 3e). Specifically, numbers 241 of activated cTfh1 cells in Flu+ patients were significantly higher than the cTfh2 and cTfh17 242 subsets, at both acute and follow-up timepoints (Fig. 3e). Further, cTfh1 responses strongly 243 correlated with ASC responses during acute influenza virus infection (Fig. 3f), but less so for 244 cTfh2 and cTfh17 subsets (Supplementary Fig. 3). Acute ASC responses also correlated with 245 high antibody responses $(\log_2(HAI/10)>2 \text{ or } HAI>40, Fig. 3g)$. However, acute cTfh responses 246 did not significantly correlate with antibody responses, perhaps due to the low titres observed in 247 some patients during acute infection, in contrast to a vaccination response where IIV-induced 248 cTfh1 responses correlated with the fold-change in antibody titres (d28 over d0 baseline)⁴.

249 To evaluate influenza-specific memory B cell responses during natural influenza virus 250 infection in comparison to vaccination, recombinant HA probes relevant to the 2014-2017 251 vaccine strains were used to detect class-switched IgD⁻ HA-specific B cells in Flu+ patients 252 (Fig. 3h, Supplementary Fig. 2b). These rHA probes have been extensively validated for their 253 specificity^{4,32,33}. Numbers of rHA⁺IgD⁻ B cells in total and per probe did not significantly 254 change between acute and follow-up timepoints (Fig. 3i), and were comparable to the magnitudes observed following IIV⁴. Phenotype and isotype distributions of the total B cells 255 remained stable between acute and follow-up timepoints (Fig. 3j,k). Specifically, rHA⁺IgD⁻ B 256 cells for H3 and B probes were more CD2110CD27hi activated memory in proportion at the acute 257 258 timepoint compared to follow-up (H3: p=0.0007, B: p=0.0017), before becoming more CD21^{hi}CD27^{hi} resting memory at follow-up compared to acute timepoints (H3: p=0.0004, B: 259 260 p < 0.0001) (Fig. 3j,l top panels). Conversely, in a healthy vaccinated cohort, the resting memory 261 phenotype was most prominent at baseline, before becoming more activated memory from days 262 7-28 following IIV (Fig. 3m, top panel). The isotype distribution in Flu+ patients was enriched 263 for IgG⁻IgM⁻ cells (mostly IgA⁺) for H3, and IgA⁺ cells for the B-probe at acute timepoints, 264 before becoming largely IgG^+ at follow-up for each probe (Fig. 3j,l bottom panels). In contrast, 265 the isotype distribution of rHA^+IgD^-B cells did not change in healthy donors following IIV 266 (Fig. 3m, bottom panel). Thus, our analyses show striking differences after influenza virus 267 infection compared to vaccination of recruited rHA⁺IgD⁻ B cells at both phenotypic and isotype 268 levels.

Although patients' HA-specific B cell responses did not positively correlate with their acute antibody responses which were generally low, there was a significant positive correlation between activated or resting memory HA-specific B cells with their acute ASC response, as well as resting memory HA-specific B cells with the acute cTfh responses (**Supplementary Fig. 4**).

It is made available under a CC-BY-NC-ND 4.0 International license .

- Taken together, we show prominent activation of cTfh1 cells during acute influenza virus infection, at the time of the ASC and influenza-specific memory B cell responses.
- 275

292

276 Influenza-specific adaptive CD8⁺ and CD4⁺ T cells respond early after infection

277 Our previous work showed that rapid recovery from severe A/H7N9 was associated with early IFN- γ -producing CD8⁺ T cell responses, while late recovery involved a network of humoral 278 (Abs) and cellular (CD8⁺, CD4⁺, NK) responses¹². Here, Flu+ patients' PBMCs were incubated 279 280 with live seasonal H1N1, H3N2, B/YAM and B/VIC viruses to measure influenza-specific 281 innate (NK, $\gamma\delta$, CD161⁺TRAV1-2⁺ or MAIT cells) and adaptive (CD4⁺ and CD8⁺ T cells) 282 immune responses elicited via IFN- γ production after 18 hrs (Fig. 4a,b, Supplementary Fig. 283 **5a**). Kinetics of influenza-specific IFN- γ -producing cells across days after disease onset showed 284 low numbers of IFN-y-producing populations across all cell subsets at patients' admission. 285 These however increased over the course of infection, before stabilizing at convalescence (Fig. 286 **4c**). Despite lymphopenia, a fixed number of cells were added to the assay, and therefore the 287 ability of adaptive CD8⁺ and CD4⁺ T cells to generate IFN- γ -responses, as a frequency per 288 subset, continued to increase during acute infection until ~15 days after disease onset (Fig. 4d). 289 Conversely, for innate cells, their ability to produce IFN- γ responses did not change, further 290 suggesting that adaptive T cells can increasingly respond to the virus during acute infection and 291 are the main drivers of early recovery.

293 Cytolytic potential of MAIT, NK and CD8⁺ T cells in Flu+ patients

294 To assess the cytolytic potential within the Flu+ patients' cell subsets, we measured cytotoxic 295 molecules: granzymes (A, B, K and M) and perforin (Supplementary Fig. 6a). Overall, MAIT 296 cells had the highest frequency of total cytotoxic molecules expressed, followed by NK cells and 297 $CD8^+$ T cells, with minimal production in $CD4^+$ T cells (**Fig. 4e**). However, for MAIT cells, the 298 Flu+ patients at acute and convalescence exhibited significantly lower levels compared to 299 healthy donors (demographics in **Supplementary Table 4**), but on the contrary for NK cells, 300 possibly suggesting differences in degranulation kinetics. No differences were observed for 301 CD8⁺ and CD4⁺ T cell subsets. Individual expression of cytolytic molecules revealed different 302 patterns between cell subsets and cytolytic molecules (Fig. 4f). Patient NK cells had 303 significantly higher levels of granzymes (A, B, M) and perforin compared to healthy donors, but 304 significantly lower levels of granzyme K. Patient MAIT cells expressed lower levels of 305 granzyme A compared to healthy donors, while patient MAIT and $CD8^+$ T cells had lower 306 granzyme K and perforin expression. No significant differences were observed between acute 307 and follow-up subsets. Furthermore, co-expression of multiple cytolytic molecules (4+) was 308 significantly reduced in Flu+ patients, both at acute and follow-up, compared to healthy 309 individuals across all cell subsets (NK cells: acute vs healthy p=0.0002, p<0.0001 for all 310 comparisons) (Fig. 4g), most likely reflecting their degranulation activities during influenza 311 infection.

312

313 Immune dynamics of activated memory influenza-specific CD8⁺ and CD4⁺ T cell responses

To dissect epitope-specific CD8⁺ and CD4⁺ T cells during acute IAV infection, we performed 314 315 patient-specific tetramer staining, utilizing an extensive range of peptide/MHC class-I and class-316 II tetramers covering the most frequent HLA alleles, with an estimated population coverage of 317 63-100% across all ethnicities (Fig. 5a, Supplementary Table 5). Following tetramer-318 associated magnetic enrichment (TAME), robust tetramer⁺CD8⁺ T cell populations were 319 detected for all donors (n=19) and specificities tested directly ex vivo (Fig. 5b,c, 320 Supplementary Fig. 6b,c), even when using 10-20% less cell numbers generally required for successful detection of antigen-specific CD8⁺ T cells in healthy donors³⁴⁻³⁶. In 17 patients, 321 322 tetramer⁺CD8⁺ T cell populations were detected at all the timepoints, while two patients had 323 tetramer⁺CD8⁺ T cells directed towards the subdominant B7-NP epitope detectable only at 324 follow-up. For comparison, A2-M1-tetramer⁺CD8⁺ T cells were also measured in Flu- patients 325 (n=4/4 detected) (Fig. 5d). Apart from CD8⁺ T cells, we also identified influenza-specific CD4⁺ 326 T cells in 5/5 H3N2-infected patients with either HLA-DR*01:01-, DR*04:01- or DR*11:01-

It is made available under a CC-BY-NC-ND 4.0 International license .

327 HA-tetramers (**Fig. 5e,f**), despite ~10-fold lower numbers of antigen-specific CD4⁺ T cells *ex* 328 *vivo*. DR*15:02-HA tetramers were also tested but yielded no specific cells in 2/2 patients.

329 Overall, tetramer precursor frequencies (where 10^{-3} denotes 1 per 1,000 cells or 1e-3), 330 were stable across timepoints, with no significant differences observed between acute and 331 follow-up (Fig. 5f). Pooled tetramer⁺CD8⁺ T cell precursor frequencies in Flu+ patients 332 (mean±SD, range: 2.62e-4±6.37e-4, 8.07e-7 to 3.56e-3) and Flu- patients (7.00e-5±8.11e-5, 333 8.38e-6 to 2.65e-4) were significantly higher 79-fold (p<0.0001) and 21-fold (p=0.0026), respectively, than pooled tetramer⁺CD4⁺ T cells ($3.30e-6\pm3.20e-6$, 6.19e-7 to 1.17e-5) 334 335 (Supplementary Fig. 6d). Frequencies of pooled tetramer⁺ $CD8^+$ T cells were similar between 336 Flu+ and Flu- patients and fell within the ranges we described previously for HLA-A2⁺ H7N9-Flu+ patients^{37,38}. 337

338 Although the frequency of tetramer⁺ $CD8^+$ T cells were similar between acute and 339 follow-up timepoints in Flu+ patients, and Flu+ versus Flu- patients, the activation phenotypes 340 markedly differed. Based on four activation markers expressed (CD38, HLA-DR, PD-1 and 341 CD71), higher levels of activation were detected at the acute timepoint compared to follow-up 342 (Fig. 5g, Supplementary Fig. 6e). Notably, in Flu+ patients, expression of two or more 343 activation markers was most evident between days 6-10 of disease onset for A2-M1⁺CD8⁺ T 344 cells, which was in stark contrast to the mainly single-PD-1 expressing or non-activated 345 phenotypes exhibited among the Flu+ follow-up samples, Flu- patients (Fig. 5h), and the parent 346 $CD8^+$ T cell populations. High levels of activation at acute compared to follow-up samples were 347 clearly observed across all tetramer⁺CD8⁺ T cell specificities and, despite limited numbers, in 348 tetramer⁺CD4⁺ T cells when compared to parental CD8⁺ and CD4⁺ T cell populations (**Fig. 5i**, 349 Supplementary Fig. 7).

350 Similarly, analysis of CD27/CD45RA/CD95 phenotypes showed significant differences 351 in the activation of tetramer⁺ $CD8^+$ and $CD4^+$ T cells in Flu+ patients when compared to the 352 parental CD8⁺ and CD4⁺ T cell populations at acute and follow-up timepoints. In general, 353 among Flu+ patients, tetramer⁺CD8⁺ T cells consisted of central memory-like (Tcm, 354 CD27⁺CD45RA⁻) and, to a lesser extent, effector memory-like (Tem, CD27⁻CD45RA⁻) 355 phenotypes, while tetramer⁺CD4⁺ T cells were predominantly of Tcm-like cells. (Fig. 5j, 356 Supplementary Fig. 6f). These proportions remained stable across timepoints but were 357 significantly enriched in Tcm compared to the overall $CD4^+$ and $CD8^+$ T cell populations, 358 respectively.

359 Overall, we show an extensive breadth of highly activated, non-cultured, *ex vivo* 360 influenza-specific memory $CD4^+$ and $CD8^+$ T cells detected during acute IAV infection, which 361 were still present in a less activated state following recovery.

362

363 Immune correlates of influenza severity

364 We also probed clinical, genetic and immune correlates of influenza severity and patients' 365 recovery. We found no significant associations between influenza disease severity (SOFA 366 scores 0-6, clinical presentation: ILI and/or pneumonia), clinical parameters (age, sex, influenza 367 strain, days of disease onset, days in hospital, risk factors and vaccination status) and genetic 368 host factors (IFITM3 rs34481144 SNP alleles). This might be as the majority of hospitalized 369 DISI patients were already in high-risk groups based on their co-morbidities/risk factors (86% 370 Flu+, 70% Flu-), including chronic respiratory disease (61% Flu+, 40% Flu-). Furthermore, 371 patients infected with seasonal influenza viruses experienced less severe disease, with short 372 hospital stays, no requirements for mechanical ventilation, and only one patient requiring ICU for one day, in contrast to the more severe avian H7N9-infected patients¹⁸. 373

To investigate any potential links between the overall breadth of immune responses in human influenza disease, including cytokines, antibodies, ASCs, activated cTfh1s, IFN- γ producing innate (NK, $\gamma\delta$ T, MAIT cells) and adaptive (CD4⁺ and CD8⁺ T cells) immune cells, and key clinical/genetic parameters and SOFA scores as a measure for disease severity, we generated heat maps with all of the above mentioned parameters. Unsupervised heat maps of acute and convalescent timepoints were generated for both Flu+ (**Fig. 6a,b, Supplementary Fig. 8a,b**) and Flu- groups, as well as the entire cohort (**Supplementary Fig. 8c-e**). For Flu+ at

It is made available under a CC-BY-NC-ND 4.0 International license .

381 the acute timepoints, regions of relatively lower cytokine levels of IL-6, MIP-1 α , IL-8, MIP-1 β , 382 MCP-1, were linked to higher levels of functional IFN- γ -producing immune cells, ASCs and 383 activated cTfh1s (Fig. 6a). As shown in Fig. 1j, these cytokines were strongly positively 384 correlated to each other. At convalescence, lower cytokine regions were linked to higher IFN-y-385 producing immune cells, but not ASCs or activated cTfh1 cells, which peaked during acute 386 infection (Fig. 6b). In both acute and convalescent phases, reciprocal regions of higher 387 cytokines levels and lower IFN- γ -producing immune cells (and lower ASCs and activated cTfh1 388 cells for acute) were observed. However, these observed regions were not defined specifically 389 by SOFA scores or other clinical/genetic parameters.

Based on the functional implications of IFN-y-producing cells detected here and our 390 previous H7N9 study¹², we analyzed specifically the numbers of IFN- γ -producing cells across 391 392 acute (V1) and convalescent timepoints (Fup) as a function of patients' disease severity via 393 binned SOFA scores due to unequal numbers of SOFA scores across the cohort, skewing 394 towards low (0-1) SOFA scores, classifying the least severe. At the earliest acute timepoint 395 (V1), decreases in innate IFN- γ -producing $\gamma\delta T$ and MAIT cells were significantly associated 396 with more severe patients with higher SOFA scores (2-6) (Fig. 6c), but not for NK cells, CD4⁺ 397 and $CD8^+$ T cells. In contrast, at convalescence, lower adaptive IFN- γ -producing $CD4^+$ and $CD8^+$ T cell responses were associated with higher severity (Fig. 6c). These results indicated 398 399 that early influenza-specific NK, CD4⁺ and CD8⁺ T cell responses were important in driving patients' recovery from influenza disease, and less severe patients had more robust responses at 400 401 convalescence, while deficiencies in early innate $\gamma\delta T$ and MAIT cell responses impacted disease 402 severity.

403

404

405 **Discussion**

406 We studied longitudinal samples obtained from patients hospitalized with influenza disease to 407 determine how innate and adaptive immune cellular responses work together to resolve human 408 influenza disease. Influenza susceptibility was associated with high co-morbidities, including 409 people with chronic respiratory disease and immunosuppressed, lower antibody responses and 410 lower rates of vaccination in our cohort. Influenza infection was associated with positively 411 correlated clusters of IL6/IL-8/MIP-1a/MIP-1B cytokines. Antibody responses were low at 412 hospitalization but increased against current and older strains at convalescent phase. The 413 kinetics of activated cTfh-type 1 cells correlated with ASCs and influenza-specific memory B-414 cell responses, which differed to vaccination-induced B-cell responses. While IFN-y-producing 415 innate cell responses were unchanged, influenza-specific CD4⁺ and CD8⁺ T cell responses 416 increased early from disease onset and tetramer⁺ CD4⁺ and CD8⁺ T cells were highly activated. 417 Collectively, these adaptive cellular mechanisms of cTfh cells, ASCs, influenza-specific B cells 418 and T cells all preceded patients' recovery, similarly to that recently detailed in our COVID-19 419 case report³⁹.

420 Similarly broad and early immunologic analyses of matched hospitalized ILI controls 421 and follow-up samples for both Flu+ and Flu- patients after ~30 days post-discharge have not 422 previously been reported. Our work expands substantially on the SHIVERS study, which 423 included follow-up sampling with blood samples collected from mild non-hospitalized and 424 severe hospitalized influenza-infected patients at the acute phase and at 2 weeks post-enrolment during the 2013 New Zealand winter seasons (Aug-Oct)²⁶. The SHIVERS cohort was similar to 425 426 DISI, enrolling 27 hospitalized patients predominantly infected with a H3N2 virus (83%) and 427 76% with an underlying condition. However, our study differed from the SHIVERS study by the 428 more rapid enrollment following symptom onset (DISI: 4.5±4.4 days (mean±SD) compared to 429 SHIVERS:10.7±4.8 days) and our patients were hospitalized for longer (DISI median of 4 days 430 (range 1-38 days) compared to SHIVERS median of 2 days (1-10 days). Rapid recruitment and 431 longer hospitalization with serial sampling enabled the capture of integral immune response 432 kinetics very early during the first week of infection, at a time critical for determining patient 433 outcome.

It is made available under a CC-BY-NC-ND 4.0 International license .

Our cytokine analyses showed that inflammatory cytokines IL-6, IL-8, MIP-1 α and 434 435 MIP-1 β were strongly positively correlated with each other, after adjusting for age and the 436 sampling days from disease onset, and supports previous studies on their collective role as biomarkers for influenza severity¹⁸⁻²¹. These cytokine correlations were still robust following 437 438 recovery at the convalescenct phase compared to other cytokines that were only correlated with 439 each other during acute infection. Furthermore, lower expression of IL-6, IL-8, MIP-1 α and 440 MIP-1 β were associated with higher IFN- γ -producing immune cells following influenza virus 441 infection assay, as well as ASCs and activated cTfh1 cells, and vice versa.

442 For antibody responses, HAI antibody titres were lower in Flu+ patients during acute 443 infection compared to Flu- patients and healthy controls, but increased significantly following 444 recovery against the infected strain and previous strains from the same subtype. It is unclear 445 whether the SHIVERS study compared antibody responses between acute versus convalescent 446 phase within mild non-hospitalized and severe hospitalized patient groups, although they did not 447 observe any differences when comparing antibody responses of mild versus severe groups at 448 both acute and convalescent timepoints²⁶. Given that we observed back-boosting of cross-449 reactive antibody responses post-infection at the follow-up timepoint, we postulate that having a 450 natural influenza virus infection, compared to a vaccine-induced response, elicits more effective 451 cross-reactive antibody responses post viral clearance warranting further investigations. Furthermore, acute GMT antibody titres were all below 40 and lower than the Flu- group 452 453 suggesting that these antibody levels were not protective prior to infection. These findings 454 provide a strong argument for influenza vaccination since the Flu+ group had lower vaccine 455 coverage (48%) than the Flu- group (65%) and supports WHO's guideline of 40 being the 50% 456 protective cut-off which has been controversial. Influenza vaccination is of utmost importance in 457 this cohort given that 86% of Flu+ patients had a significant risk factor for severe influenza 458 disease and 71% of those having a chronic respiratory disease.

459 We have recently performed a comprehensive study to measure influenza-specific B and 460 T cell responses following seasonal IIV in healthy individuals⁴. Vaccine-induced antibody 461 responses positively correlated with increases in ASCs, influenza-specific memory B cells and a 462 subset of activated cTfh cells. Similarly, during acute influenza disease, we show prominent 463 activation of cTfh1 cells, which correlated with ASC responses and memory influenza-specific 464 B cells. In contrast, numbers of cTfh1 did not correlate with antibody titres at acute, follow-up 465 or fold-change titres. Only ASC numbers positively correlated with higher acute antibody titres 466 of 40 and above, again supporting a cut-off titre of 40 as a measure of protection. The role of cTfh cells as surrogates to germinal center Tfh cells have been described during dengue 467 infection⁴⁰ and very recently by our group in a COVID-19 patient³⁹. However, to the best of our 468 469 knowledge, there have been no previous reports on human cTfh cells following natural influenza 470 virus infection.

471 Interestingly, phenotypic analysis of the memory influenza-specific B cell response 472 showed contrasting profiles induced by infection versus vaccination. During acute infection, 473 influenza-specific B cells were of an activated-memory phenotype comprising IgG and IgA isotypes but were predominantly a resting-memory IgG⁺ population at convalescence. 474 475 Conversely, IIV induced an expansion of activated-memory influenza-specific B cells but there 476 were no changes in the isotype distribution which were predominantly $IgG^+ B$ cells, given that 477 the influenza vaccine is not delivered to a mucosal site. IgA⁺ memory B cells are able to localize 478 in the blood and mucosal sites of inflammation such as the respiratory tract during influenza 479 virus infection to provide a rapid immune response, while IgG^+ memory B cells generally 480 circulate throughout the body⁴⁵. Therefore, in accordance with our earlier antibody findings, we 481 suggest that future B cell-based influenza vaccines promoting cross-reactive B cell responses 482 encompassing both activated-memory IgA⁺ and IgG⁺ subclasses may provide further protection 483 at the site of infection.

484 Our study utilized a whole live virus assay to measure the kinetics of influenza-specific 485 responses in NK cells, $\gamma\delta$ T cells and CD161⁺TRAV1-2⁺ MAIT cells (innate-like), and CD8⁺ 486 and CD4⁺ T cells (adaptive). We observed robust and increasing proportions of adaptive CD8⁺ 487 and CD4⁺ T cell responses within the first 2 weeks of infection, despite the patients' overall

It is made available under a CC-BY-NC-ND 4.0 International license .

488 lymphphopenic state, illustrating the ability of these cell types to drive patient recovery. In contrast, innate lymphocytes did not increase in their ability to respond to influenza virus 489 490 infection by cytokine production, and lower IFN- γ -producing $\gamma\delta$ T cells and MAIT cells were 491 significantly associated with higher disease severity based on SOFA scores at the earliest V1 492 timepoint. Similarly, we previously showed the robustness of the adaptive CD8⁺ and CD4⁺ T 493 cell immune response in driving recovery from severe H7N9 disease¹². These findings have 494 important implications for future influenza vaccines because, apart from the CD4⁺ T cell help 495 compartment, IIV fails to induce CD8⁺ T cell responses nor any innate responses from NK cells, 496 $\gamma\delta$ T cells and MAIT cells, as we previously reported⁴.

497 We probed influenza-specific T cells ex vivo using a range of peptide/MHC class I and 498 class II tetramers covering the most frequent HLA alleles with an estimated population coverage 499 of 63-100% across all ethnicities. Tetramer⁺ CD8⁺ and CD4⁺ T cells were highly activated at 500 acute timepoints, compared to a less activated profile at follow-up, and mainly expressed 501 combinations of PD-1 with CD38 and CD71, and HLA-DR to a lesser extent. In contrast to severe H7N9 influenza¹³, Ebola⁴⁶ and COVID-19 disease³⁹, with prominent CD38⁺HLA-DR⁺ 502 503 populations in the total CD8/CD4 compartments, we did not observe marked populations of 504 $CD38^{+}HLA-DR^{+}$ T cells in either tetramer⁺ or parent populations, perhaps reflecting a less 505 severe cohort of diseased patients in our DISI study. Nonetheless, we provide acute and 506 convalescent populations of rare HA₃₀₆₋₃₁₈-specific CD4⁺ T cells in H3N2-infected patients that were HLA-DR*01:01⁺ (n=3), HLA-DR*04:01⁺ (n=1) or HLA-DR*11:01⁺ (n=1), which 507 complements other studies assessing cells in HLA-DR*04:01⁺ healthy donors and rheumatoid 508 arthritis patients following influenza vaccination^{47,48}. Therefore, our results represent the 509 510 broadest array of influenza-specific tetramer⁺ T cell responses during acute influenza infection, 511 providing essential tools for future T cell-immune monitoring of newly-emerging influenza 512 viruses.

Tracking antibody, B and T cell responses (and other immune mediators) may be predictive of patients' severity or recovery from influenza virus infections that require hospitalization. Our current analyses of immunological and virological parameters within a clinical hospital framework provide a unique and key dataset on the mechanisms underpinning influenza severity and susceptibility in the human population. Furthermore, these efforts represent a substantial progression to elucidate the host immune responses underlying the recovery from this acute disease as well as other infectious diseases such as COVID-19³⁹.

- 520
- 521

522 **Online Methods**

523 Study participants and design

524 The Dissection of Influenza-Specific Immunity (DISI) cohort enrolled consenting adult patients 525 admitted to The Alfred hospital during the 2014-2017 peak influenza seasons with influenza-526 like illness. Influenza-positive patients were PCR-confirmed (n=44), while ILI influenza-527 negative patients with other respiratory diseases were treated as negative controls (n=20). 528 Bloods were collected within 24-72 hours of hospital admission (Visit 1, V1), every 2-5 days 529 until discharge (V2, V3, V4 etc), then followed up approximately 30 days later. Nasal swabs 530 were collected at V1 and V2 timepoints while in hospital. Clinical data collection included 531 vaccination status, sequential (sepsis-related) organ failure assessment (SOFA) score²⁸ as a 532 measure of disease severity, and any significant risk factors (Supplementary Tables 1 and 2).

The H7N9-infected hospitalized patient cohort (n=18) has previously been described¹⁸. Healthy adults vaccinated in 2015 (TIV, n=16) and 2016 (QIV, n=26) have previously been described in detail⁴, where blood samples were collected prior to vaccination (day -1 or 0) and on days 7, 14 and 28 following vaccination. Healthy blood donors were recruited from The University of Melbourne and Deepdene Surgery. Buffy packs were sourced from Australian Red Cross Lifeblood, respectively (**Supplementary Table 4**).

Human experimental work was conducted according to the Declaration of Helsinki
Principles and according to the Australian National Health and Medical Research Council Code
of Practice. All participants provided written informed consent prior to the study. The study was

It is made available under a CC-BY-NC-ND 4.0 International license .

542 approved by the Alfred Hospital (ID #280/14) and University of Melbourne (ID #1442952.1 and #1443389.4) Human Research Ethics Committees. Up to 40 mls of DISI patient blood was 543 544 collected in sodium heparin tubes (including 1 serum tube) and processed within 24 hours. Up to 545 60 mls was collected from healthy donors and ~50-60 ml for buffy packs. PBMCs were isolated 546 by Ficoll-Paque (GE Healthcare, Uppsala, Sweden) density-gradient centrifugation and 547 cryopreserved. DNA was extracted from the granulocyte layer using a QIAamp DNA Mini Kit 548 (Qiagen, Hilden, Germany) and sent to the Victorian Transplantation and Immunogenetics 549 Service (Australian Red Cross Lifeblood, West Melbourne, Victoria, Australia) for HLA class I 550 and class II molecular typing using the Luminex platform and microsphere technology (One 551 Lambda, Canoga Park, CA, USA), with LABType SSO HLA typing kits (One Lambda). Nasal 552 swab samples were kept cold during transport and stored at -80° C within 4 hours.

In cases where fewer than the total number of donors were analyzed (**Supplementary Table 6**), DISI patients were selected for influenza-specific cellular assays based on their influenza status and remaining sample availability, such as the class I and II TAME experiments which were carried out on IAV⁺ patients and relied on HLA type and tetramer availability. HIVpositive patients (n=5, **Supplementary Table 2**) were not included in such experiments to fulfil biocontainment regulations. No other blinding or randomization protocols were applied and no outliers (i.e. the two death patients) were excluded.

560

561 IFITM3 SNP analysis

Amplification of *exon 1* rs12252 region was performed by PCR on genomic DNA using forward (5'-GGAAACTGTTGAGAAACCGAA-3') and reverse (5'-CATACGCACCTTCACGGAGT-3') primers, as previously described⁴⁹. Amplification of the rs34481144 promotor region was performed using forward (5'-GGAAACTGTTGAGAAACCGAA-3') and reverse (5'-CATACGCACCTTCACGGAGT-3') primers, as described¹⁷.

567

568 Cytokine analysis

569Patient's sera or plasma was diluted 1:4 for performing cytokine bead assay (CBA) using the570Human CBA Kit (BD Biosciences, San Jose, California, USA), according to manufacturer's571instructions. Capture beads included IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-1β,572IFN-α, MIP-1α, MIP-1β, MCP-1, CD178/FasL, granzyme B, RANTES, TNF and IFN-γ.573Samples were also diluted 1:100 for RANTES. A limited panel of cytokines for H7N9 patients574have already been described¹⁸.

575

576 Viral sequencing

577 Viral isolates from nasal swabs were sequenced for HA using standard Sanger sequencing
578 methods. HA phylogenetic neighbour-joining trees were produced using Geneious 9.0.4
579 software. Sequences are on the GISAID database with ID numbers of EPI_ISL_312219-312221,
580 312673-312674.

581

582 Viruses

Influenza A (A/H1N1/California/7/2009, A/H3N2/Switzerland/9715293/2013 and H3N2/Hong Kong/4801/2014) and B (B/YAM/Phuket/3073/2013 and B/VIC/Brisbane/60/2008) viruses were grown in 10-day old embryonated chicken eggs at 33°C for 72 hours. Allantoic fluid was harvested and titrated using standard plaque assays in MDCK cells for use in the influenza infection assays. Other viruses (**Supplementary Table 3**) were sourced from the WHO Collaborating Centre for Reference and Research on Influenza (Melbourne, Australia).

589

590 Hemagglutination inhibition assay

591 RDE-treated sera or plasma samples were assessed for antibody titres against a panel of 592 influenza viruses (**Supplementary Table 3**) using standard HAI assays with 1% turkey red 593 blood cells (H1N1 and IBV) or 1% guinea pig red blood cells in the presence of oseltamivir 594 (H3N2), according to WHO guidelines. HAI titres were reported as the reciprocal of the highest

It is made available under a CC-BY-NC-ND 4.0 International license .

595 dilution of serum where hemagglutination was completely inhibited, then divided by 10 and 596 log₂-transformed.

597

598 *Flow cytometry*

599 Fresh whole blood was used to measure absolute cell numbers using BD TruCount tubes and 600 BD MultiTest (CD3 FITC/CD16+CD56 PE/CD45 PerCP/CD19 APC, #340500) according to 601 manufacturer's instructions (BD Biosciences), as well as Tfh and ASC populations as 602 described⁴. Thawed PBMCs from Flu+ patients were stained with recombinant (r) HA probes 603 from H1 (California/7/2009), H3 (Switzerland/9715293/2013 or Hong Kong/4801/2014) and B strains (Phuket/3073/2013 or Brisbane/60/2008)^{4,32}, as described, except anti-IgA was not 604 included in rH1 and rH3 probe panels. PBMCs stained with other antibody panels are indicated 605 606 under specific assays. TruCount/MultiTest samples were acquired on a BD CantoII. All other 607 samples were acquired on a BD LSRII Fortessa. Flow cytometry data were analyzed using 608 FlowJo v10 software.

609

610 Influenza virus infection assay

611 Thawed PBMCs (<1.5e6) from DISI Flu+ patients were cultured overnight at $37^{\circ}C/5\%$ CO₂ 612 with their cognate live egg-grown virus (MOI=4), essentially as described^{4,12}, for a total of 22 613 hours before cells were harvested, then cell surface and intracellularly stained with Panel 1a or 614 1b (**Supplementary Table 7**) using the BD Cytofix/Cytoperm Kit according to manufacturer's 615 instructions. A no virus culture was included as a background staining control, which was 616 subtracted from the virus culture.

617

618 Tetramer-associated magnetic enrichment (TAME)

619 TAME was performed on thawed PBMCs (3-38e6) for the detection of influenza-specific CD4⁺ and CD8⁺ T cells, as described^{36,37}. Peptide/MHC class I and class II monomers (Fig. 5a) were 620 621 generated in-house^{50,51}, before 8:1 molar ratio conjugation with either PE-streptavidin (SA) or 622 APC-SA (BD Biosciences) to form tetramers. Briefly, cells were stained (1:100-200 dilution) 623 with PE- (A2-M1, B7-NP, B8-NPs, B18-NP and B35-NPs) or APC-labelled (A1-NPs, A2-M1, 624 A24-PB1, A68-NP, B57-NP and DR1/4/11-HAs) tetramers for 1 hour at room temperature 625 before dual-magnetic enrichment with anti-PE and anti-APC MicroBeads (Miltenyi Biotec, Bergisch Galdbach Germany) as described^{36,38}. Tetramers restricted to the same HLA were 626 627 added together at the same dilution. Unenriched, enriched and flow-through fractions were cell 628 surface stained with Panel 2a (Flu+) or 2b (Flu-, follow-up samples only) (Supplementary 629 Table 7), fixed with 1% PFA, then acquired by flow cytometry. Panel 2b samples were fixed and permeabilized using the eBioscienceTM Foxp3/Transcription Factor Staining Buffer Set 630 631 (Thermo Fisher Scientific, Carlsbad, CA, USA). Samples with cell events just below 10, 632 especially for tetramer⁺CD4⁺ T cells, were not further characterized phenotypically using these 633 staining panels.

634

635 Expression of cytolyic molecules

Flow-through fractions of DISI patients following TAME or thawed PBMCs from healthy
donors (Supplementary Table 4) were stained with Panel 3 (Supplementary Table 7) for
measuring granzymes (A, B, K and M) and perforin using the Foxp3/Transcription Factor
Staining Buffer Set.

640

641 Statistical analyses

642 Statistical significance was assessed using GraphPad Prism v8 software unless stated otherwise. 643 Mann-Whitney (unpaired) and Wilcoxin (paired) tests were two-tailed. Friedman (matched) and 644 Kruskal-Wallis (unmatched) tests were used to compare more than two groups. Tukey's 645 multiple comparison test compared row means between more than two groups. Partial 646 correlation plots (Fig. 1j) showing significant (FDR-adjusted *p*-value < 0.05) coloured squares 647 were partialed to account for the variance caused by $\log_{10}(age)$ and the sampling days after 648 disease onset. To build antibody landscapes (Fig. 2f), local regression (LOESS) was applied in R 3.5.3⁵². LOESS with 95% confidence intervals was also used to plot Fig. 3c, 4c and 4d. Linear 649

It is made available under a CC-BY-NC-ND 4.0 International license .

relationships between day of sample and percent of IFN- γ producing cells were assessed with ordinary least squares (Im function) in R with 95% confidence intervals shaded in grey and correlation coefficients (r²) reported in Fig 4d. Correlations (**Fig. 3f,g, Supplementary Fig. 4**) were assessed using Spearman's correlation coefficient (r_s). Polyfunctionality pie charts (**Fig. 4g**) were generated using Pestle v1.8 and Spice v5 software⁵³ and *p*-values were calculated using Permutation Test. *P*-values lower than 0.05 were considered statistically significant and exact *p*values are shown in the figure. All statistical tests are indicated in the figure legends.

657 658 Data aw

658 Data availability

- The data that support the findings of this study are available from the corresponding author upon request.
- 661
- 662
- 663

664 **References**

- 665
- 666 1. G. B. D. Influenza Collaborators. Mortality, morbidity, and hospitalisations due to
 667 influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of
 668 Disease Study 2017. *Lancet Respir Med* 7, 69-89 (2019).
- 669 2. Iuliano, A.D., *et al.* Estimates of global seasonal influenza-associated respiratory
 670 mortality: a modelling study. *Lancet* **391**, 1285-1300 (2018).
- 671 3. Krammer, F., et al. Influenza. Nat Rev Dis Primers 4, 3 (2018).
- Koutsakos, M., *et al.* Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. *Sci Transl Med* **10**(2018).
- McMichael, A.J., Gotch, F.M., Noble, G.R. & Beare, P.A. Cytotoxic T-cell immunity to
 influenza. *N Engl J Med* 309, 13-17 (1983).
- 6. Epstein, S.L. Prior H1N1 influenza infection and susceptibility of Cleveland Family
 678 Study participants during the H2N2 pandemic of 1957: an experiment of nature. *J Infect*679 *Dis* 193, 49-53 (2006).
- Kreijtz, J.H., *et al.* Cross-recognition of avian H5N1 influenza virus by human cytotoxic
 T-lymphocyte populations directed to human influenza A virus. *J Virol* 82, 5161-5166
 (2008).
- 8. Sridhar, S., *et al.* Cellular immune correlates of protection against symptomatic pandemic influenza. *Nat Med* 19, 1305-1312 (2013).
- 685 9. Wilkinson, T.M., *et al.* Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. *Nat Med* **18**, 274-280 (2012).
- 10. Zhao, Y., *et al.* High levels of virus-specific CD4+ T cells predict severe pandemic
 influenza A virus infection. *Am J Respir Crit Care Med* 186, 1292-1297 (2012).
- Hayward, A.C., *et al.* Natural T Cell-mediated Protection against Seasonal and Pandemic
 Influenza. Results of the Flu Watch Cohort Study. *Am J Respir Crit Care Med* 191, 1422-1431 (2015).
- Wang, Z., *et al.* Recovery from severe H7N9 disease is associated with diverse response
 mechanisms dominated by CD8(+) T cells. *Nat Commun* 6, 6833 (2015).
- Wang, Z., *et al.* Clonally diverse CD38(+)HLA-DR(+)CD8(+) T cells persist during
 fatal H7N9 disease. *Nat Commun* 9, 824 (2018).
- k van de Sandt, C.E., *et al.* Human cytotoxic T lymphocytes directed to seasonal influenza
 A viruses cross-react with the newly emerging H7N9 virus. *J Virol* 88, 1684-1693
 (2014).
- Hertz, T., *et al.* HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection. *Proc Natl Acad Sci U S A* 110, 13492-13497 (2013).

It is made available under a CC-BY-NC-ND 4.0 International license

702	16.	Falfan-Valencia, R., et al. An Increased Frequency in HLA Class I Alleles and
703		Haplotypes Suggests Genetic Susceptibility to Influenza A (H1N1) 2009 Pandemic: A
704		Case-Control Study. J Immunol Res 2018, 3174868 (2018).
705	17.	Allen, E.K., <i>et al.</i> SNP-mediated disruption of CTCF binding at the IFITM3 promoter is
706		associated with risk of severe influenza in humans. Nat Med 23, 975-983 (2017).
707	18.	Wang, Z., et al. Early hypercytokinemia is associated with interferon-induced
708		transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. <i>Proc Natl</i>
709		Acad Sci U S A 111 769-774 (2014)
710	19	Lee N <i>et al.</i> Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal
711	17.	influenza among hospitalized adults <i>PLoS One</i> 6 e26050 (2011)
712	20	Oshansky CM <i>et al</i> Mucosal immune responses predict clinical outcomes during
713	20.	influenza infection independently of age and viral load Am I Respir Crit Care Med 189
714		449-462 (2014)
715	21	Hall MW <i>et al</i> Innate immune function and mortality in critically ill children with
716	21.	influenza: a multicenter study. Crit Care Med 41 , 224-236 (2013)
717	22	Valkanburg SA <i>et al.</i> The Hurdles From Banch to Badside in the Papilization and
718	22.	Implementation of a Universal Influenza Vaccine Front Immunol 0 1470 (2018)
710	23	Dunning L at al Progression of whole blood transcriptional signatures from interferon
719	23.	induced to neutronbil according in course influence. Nat Immunel 10, 625,625
720		induced to neutrophil-associated patterns in severe inititenza. <i>Nat Immunol</i> 19, 625-655
721	24	(2018).
122	24.	Fox, A., <i>et al.</i> Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiences and character CD_{2}^{0} are associated with transient NK
723	25	and I denciency and aberrant CD8 responses. PLos One 1, es1555 (2012).
724	25.	Diao, H., <i>et al.</i> Severe H/N9 infection is associated with decreased antigen-presenting
725	26	capacity of CD14+ cells. <i>PLoS One</i> 9, e92823 (2014).
726	26.	Wong, S.S., <i>et al.</i> Severe influenza is Characterized by Prolonged Immune Activation:
727	~=	Results From the SHIVERS Cohort Study. J Infect Dis 217, 245-256 (2018).
728	27.	Quinones-Parra, S., et al. Preexisting CD8+ T-cell immunity to the H/N9 influenza A
729	•	virus varies across ethnicities. <i>Proc Natl Acad Sci U S A</i> 111 , 1049-1054 (2014).
730	28.	Singer, M., et al. The Third International Consensus Definitions for Sepsis and Septic
731		Shock (Sepsis-3). JAMA 315, 801-810 (2016).
732	29.	Fonville, J.M., <i>et al.</i> Antibody landscapes after influenza virus infection or vaccination.
733		<i>Science</i> 346 , 996-1000 (2014).
734	30.	Crotty, S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 29, 621-663 (2011).
735	31.	Bentebibel, S.E., <i>et al.</i> Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with
736		antibody responses to influenza vaccination. Sci Transl Med 5, 176ra132 (2013).
737	32.	Liu, Y., et al. Cross-lineage protection by human antibodies binding the influenza B
738		hemagglutinin. Nat Commun 10, 324 (2019).
739	33.	Wheatley, A.K., Kristensen, A.B., Lay, W.N. & Kent, S.J. HIV-dependent depletion of
740		influenza-specific memory B cells impacts B cell responsiveness to seasonal influenza
741		immunisation. Sci Rep 6, 26478 (2016).
742	34.	Nguyen, T.H., et al. Maintenance of the EBV-specific CD8(+) TCRalphabeta repertoire
743		in immunosuppressed lung transplant recipients. Immunol Cell Biol 95, 77-86 (2017).
744	35.	Nguyen, T.H., et al. Understanding CD8(+) T-cell responses toward the native and
745		alternate HLA-A*02:01-restricted WT1 epitope. Clin Transl Immunology 6, e134
746		(2017).
747	36.	Nguyen, T.H.O., et al. Perturbed CD8(+) T cell immunity across universal influenza
748		epitopes in the elderly. J Leukoc Biol 103, 321-339 (2018).
749	37.	Koutsakos, M., et al. Human CD8(+) T cell cross-reactivity across influenza A, B and C
750		viruses. Nat Immunol 20, 613-625 (2019).
751	38.	Sant, S., et al. Single-Cell Approach to Influenza-Specific CD8(+) T Cell Receptor
752		Repertoires Across Different Age Groups, Tissues, and Following Influenza Virus
753		Infection. Front Immunol 9, 1453 (2018).
754	39.	Thevarajan, I., <i>et al.</i> Breadth of concomitant immune responses prior to patient recovery:

755 a case report of non-severe COVID-19. *Nat Med* **26**, 453-455 (2020).

		It is made available under a CC-BY-NC-ND 4.0 International license.
756	40.	Haltaufderhyde, K., et al. Activation of Peripheral T Follicular Helper Cells During
757		Acute Dengue Virus Infection. J Infect Dis 218, 1675-1685 (2018).
758	41.	Leong, Y.A., et al. CXCR5(+) follicular cytotoxic T cells control viral infection in B cell
759		follicles. Nat Immunol 17, 1187-1196 (2016).
760	42.	He, R., et al. Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral
761		infection. Nature 537, 412-428 (2016).
762	43.	Petrovas, C., et al. Follicular CD8 T cells accumulate in HIV infection and can kill
763		infected cells in vitro via bispecific antibodies. Sci Transl Med 9(2017).
764	44.	Mylvaganam, G.H., et al. Dynamics of SIV-specific CXCR5+ CD8 T cells during
765		chronic SIV infection. Proc Natl Acad Sci USA 114, 1976-1981 (2017).
766	45.	Auladell, M., et al. Recalling the Future: Immunological Memory Toward Unpredictable
767		Influenza Viruses. Front Immunol 10, 1400 (2019).
768	46.	McElroy, A.K., et al. Human Ebola virus infection results in substantial immune
769		activation. Proc Natl Acad Sci U S A 112, 4719-4724 (2015).
770	47.	Uchtenhagen, H., et al. Efficient ex vivo analysis of CD4+ T-cell responses using
771		combinatorial HLA class II tetramer staining. Nat Commun 7, 12614 (2016).
772	48.	Herati, R.S., et al. Successive annual influenza vaccination induces a recurrent
773		oligoclonotypic memory response in circulating T follicular helper cells. Sci Immunol
774		2 (2017).
775	49.	Clemens, E.B., et al. Towards identification of immune and genetic correlates of severe
776		influenza disease in Indigenous Australians. Immunol Cell Biol 94, 367-377 (2016).
777	50.	Gras, S., et al. The shaping of T cell receptor recognition by self-tolerance. Immunity 30,
778		193-203 (2009).
779	51.	Benati, D., et al. Public T cell receptors confer high-avidity CD4 responses to HIV
780		controllers. J Clin Invest 126, 2093-2108 (2016).
781	52.	R Core Team. R: A language and environment for statistical computing. R Foundation
782		for Statistical Computing, Vienna, Austria. (2019. <u>http://www.R-project.org/</u> .).
783	53.	Roederer, M., Nozzi, J.L. & Nason, M.C. SPICE: exploration and analysis of post-
784		cytometric complex multivariate datasets. Cytometry A 79, 167-174 (2011).
785		
786		
787	Ackn	owledgements

788 We thank Jill Garlick, Janine Roney, and the research nurses at the Alfred Hospital, Nicola Bird, 789 Kim Harland, Louise Carolan and Bernadette McCudden for their technical assistance. Thank 790 you to Professors David Fairlie and Jim McCluskey for the MR1-5'OP-RU tetramer. We also 791 thank the study participants for providing blood for research purposes.

792 793

794 Funding

795 The Australian National Health and Medical Research Council (NHMRC) NHMRC Program 796 Grant (1071916) to KK, SJT, NLG, AK, DCJ, LEB, WC supported this work. MK and SN were 797 recipients of Melbourne International Research Scholarship and Melbourne International Fee 798 Remission Scholarship. CES has received funding from the European Union's Horizon 2020 799 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 800 792532. EBC is a NHMRC Peter Doherty Fellow. MA and LH are recipients of Melbourne 801 International Research Scholarship and Melbourne International Fee Remission Scholarship. SS 802 was a recipient Victoria India Doctoral Scholarship and Melbourne International Fee Remission 803 Scholarship, University of Melbourne. The Melbourne WHO Collaborating Centre for 804 Reference Research on Influenza is supported by the Australian Government Department of 805 Health. SG is a NHMRC SRF-Level A Fellow. JR is supported by an ARC Laureate fellowship. 806 NLG is supported by a NHMRC Ideas grant, ARC Discovery Project and ARC Future 807 Fellowship. PGT is supported by the St. Jude Center of Excellence for Influenza Research and 808 Surveillance (NIAID Contract HHSN27220140006C), R01 AI 107625, R01AI136514 and 809 ALSAC. ACC is a NHMRC Career Development (level 2) Fellow. KK was supported by a

It is made available under a CC-BY-NC-ND 4.0 International license .

- 810 NHMRC Senior Research Fellowship Level B (#1102792), NHMRC Investigator Grant
- 811 (#1173871) and the University of Melbourne Dame Kate Campbell Fellowship.
- 812
- 813

814 **Conflicts of interest**

- 815 The authors declare no conflict of interest.
- 816

817 Author contributions

818 KK supervised and lead the study. KK, THON, MK, CES and LL designed the experiments. 819 THON, MK, CES, LL, LG, SS, EBC, MAu, LH, ZW, SN, AF, XX, MAb, KLL and YD 820 performed experiments. THON, MK, CES, JCC, LL, LG, EKA, TB, EBC, MAu, LH, ACH, 821 PGT and KK analyzed data. AKW and SJK provided invaluable rHA probes. SG and JR 822 provided invaluable pMHC-I/II tetramers. JC, JX, TCK and ACC recruited the patient cohorts. 823 KK, ACC, TCK, SJT, PCD, DJ, LEB, NLG and WC provided intellectual input into the study 824 design and data interpretation. THON, PGT, ACC and KK wrote the manuscript. All authors 825 reviewed and approved the manuscript.

826

827 Competing interests

- 828 All authors declare no competing interests.
- 829

830 Figure legends

831 Fig. 1. Clustering analysis of patient clinical information, genetic characteristics and 832 inflammatory cytokines. a, Flow chart of study design. b, Frequency of patients infected with 833 seasonal influenza virus strains. N values are below for total and for each year. c, Age 834 distribution by influenza A (3 unsubtyped, 7 H1N1, 24 H3N2), influenza B (3 unsubtyped, 4 835 YAM, 3 VIC) and influenza-negative (Non-flu, Flu-) patients (n=20). Virus strain colours match 836 those in (b). d, Days in hospital for DISI cohort and H7N9 cohort. c,d, Bars indicate the median 837 and IQR, statistical significance (p < 0.05) was determined using the Kruskal-Wallis test. e, 838 Frequency of universal versus risk HLA alleles between influenza-positive (Flu+) and Flu-839 patients. f,g, Pie charts of IFITM3 SNP allele genotyping at positions rs12252 and rs34481144, 840 respectively (risk allele in black). h, Box plots of rs34481144 alleles against SOFA scores 841 showing median, IQR and whiskers extending to the largest or smallest values no further than 842 1.5 times the IQR. i, Representative serum levels and distribution of pro-inflammatory cytokines 843 in patients, measured within the first 2-3 days of hospital admission (Visit 1, V1), with varying 844 disease severity. j, Partial correlation plots showing the degree of correlation between every 845 chemokine/cytokine pair in Flu+ patients at V1 and F_{up} . The colour corresponds to the 846 correlation coefficient and the size of the colored squares correspond to the FDR-adjusted p-847 value. Correlations that are not significant (p>0.05) result in white boxes.

848

849 Fig. 2. Viral analysis and antibody responses. a, H3N2 phylogenetic tree of HA amino acid 850 sequences from previous WHO reference strains in black, influenza vaccine strains in red and 851 sequences isolated from the nasal swab of 12 H3N2-infected patients in blue. Patient number is 852 followed by the year of recruitment, yes (Y) or no (N) for prior vaccination in the year of 853 infection, and "mm*" indicates whether the vaccine was a clade mismatch in that year. Scale bar 854 represents the number of substitutions per site. **b**, Antibody HAI titers of Flu+ patients at acute 855 (V1 or V2) and follow-up timepoints from the relevant infected strain (mean and SD are 856 shown). Statistical significance (p < 0.05) was determined using the Mann-Whitney test between 857 acute and follow-up per strain. c,d, Geometric mean titers (GMT) per strain in Flu+ and Flu-858 patients at acute and follow-up, and from a healthy vaccinated cohort at days 0 and 28 post-859 vaccination. b-d, Both H1N1 and H3N2 titers are shown for three A/unsubtyped patients and 860 both B/YAM/Phuket/3073/2013 and B/VIC/Brisbane/60/2008 titres are shown for three 861 B/unsubtyped patients (square symbols). e, Representative antibody landscapes from a patient 862 infected with H1N1, H3N2, B/YAM or B/VIC virus. Blue shading indicate period of potential 863 exposure based on the year born. **f**, Antibody landscapes of H1N1- and H3N2-infected (n=7 and 864 23, respectively) and H1N1- and H3N2-non-infected patients (n=45 and 29, respectively). Lines

It is made available under a CC-BY-NC-ND 4.0 International license .

865 and shading indicate the GMT and 95% confidence intervals, respectively. Gradient coloured 866 dots indicate individual titres.

867

Fig. 3. Circulating Tfh cells, ASCs and influenza-specific B cell responses. a, Representative 868 869 FACS plots of CD4⁺CXCR5⁺ cTfh subsets (cTfh1/2/17) and expression of activation markers 870 PD-1 and ICOS. b, Representative FACS plots of CD19⁺CD20^{-/lo}CD27⁺⁺CD38⁺⁺ ASCs and PD-871 $1^{+}ICOS^{+}$ activated CXCR3⁺CCR6⁻ cTfh1 cells at acute (V1 and V2) and follow-up (F_{up}) 872 timepoints. Days (d) after disease onset are shown in brackets. c, Numbers of ASC and cTfh1 873 cells of Flu+ (red) and Flu- (blue) patients after disease onset. Grey shading represents 95% 874 confidence intervals. d, Numbers of the peak ASC responses during acute ILI (Ac_{max}) versus F_{up} 875 in Flu+ (open circles, Ac_{max} n=40, F_{up} n=32) and Flu- patients (grey circles, Ac_{max} n=19, F_{up} 876 n=15). e, Peak cTfh responses of different Tfh1/2/17 subsets at Ac_{max} (Flu+n=40, Flu-n=19) 877 and F_{up} (Flu+ n=32, Flu- n=15) timepoints. **f**, Correlation (Spearman correlation coefficient, r_s) 878 between Acmax ASC and cTfh1 responses and (g) Acmax ASC responses with HAI antibody titres 879 of high (HAI≥40) and low responders (HAI<40) during acute infection. h, Representative FACS 880 plots of H1-, H3- and B-specific rHA⁺ B cells at V1 and F_{up} timepoints (days after disease onset 881 in brackets). i, Numbers of total rHA⁺ B cells and per H1-, H3- and B-specific rHA⁺ B cells at 882 acute (Ac) (n=21) and F_{up} timepoints (n=22). **j**, Representative overlay FACS plots of live total 883 B cells and rHA⁺ B cells from IBV-infected patient #29 at F_{up} for phenotype and isotype 884 characterization. k-m, Phenotype (top panel) and isotype (bottom panel) distributions of (k) 885 total B cells and (I) rHA⁺ B cells in Flu+ patients at acute (Ac=V1 and V2, V1, V2) and follow-886 up timepoints in comparison to (m) healthy vaccinated controls (n=41) pre-vaccination at 887 baseline (BL) and d7, 14 and 28 post-vaccination. d,e,i, Red bars indicate the median and IQR 888 for cell numbers. k-m, Bars indicate the mean and SD for frequencies. Statistical significance 889 (p < 0.05) was determined using the (d) Mann-Whitney test, (e) Friedman test and (k-m) Tukey's 890 multiple comparison test. Coloured *p*-values refer to each group legend within the graph.

891 892

Fig. 4. Innate and adaptive immune responses in seasonal influenza-infected patients. a-d, 893 Data following influenza virus infection assay. a, Representative FACS plots of innate (NK 894 cells, $\gamma\delta$ T cells and CD161⁺TRAV1-2⁺ MAIT cells) and adaptive (CD4⁺ and CD8⁺ T cells) 895 immune cell subsets gated on live/CD14⁻/CD19⁻ singlet lymphocytes. b, Representative FACS 896 plots measuring frequency of infection (intracellular nucleoprotein (NP) staining) and IFN- γ 897 production for each immune cell subset. Infection in PBMCs by intracellular NP-staining 898 showing consistent infectivity rates over time across the donors (Supplementary Fig. 5b). 899 MAIT cells were defined as CD161⁺TRAV1-2⁺ and were validated by the MR1-5'OP-RU-900 tetramer in 51% of samples (Supplementary Fig. 5c,d). c,d, Numbers (n=22) and frequencies 901 (n=30) of influenza-specific IFN- γ -production in patients' immune cell subsets as days of 902 disease onset where 95% confidence intervals are shaded in grey. e-g, Patient data from PBMCs

- 903 left over from flow through fraction following TAME. *NK cells were defined by live/CD14 904 /CD19⁻/CD3⁻ cells. ^MAIT cells were defined by the MR1-5-OP-RU-tetramer and anti-TRAV1-905 2 antibody. e, Frequency (mean, SD) of Flu+ patient cells expressing total cytotoxic molecules 906 at acute (includes n=16 at V1 and n=11 at subsequent visits i.e. V2, V3, or V4) and follow-up 907 timepoints (n=19), in comparison to healthy donors (n=20), except for MAIT subset where 908 n=12). f, Representative FACS plots of CD8⁺ T cells from Flu+ patient and individual 909 frequencies (mean, SD) of granzymes (A, B, K and M) and perform staining for each cell 910 subset. g, Pie charts representing the average fractions of cells co-expressing different cytotoxic 911 molecules (slices) and the combinations of granzymes and perforin molecules (arcs). Statistical 912 significance (p < 0.05) was determined using (e,f) Tukey's multiple comparison and (g) 913 Permutation tests.
- 914

Fig. 5. Influenza-specific CD4⁺ and CD8⁺ T cell responses. a, List of influenza-specific HLA class I (A, B) and class II (DR) tetramers used in the study. **b**,**c**, Concatenated FACS plots of TAME-enriched class I-tetramer⁺ cells gated on CD8⁺ T cells from Flu+ patients and (**d**) Flupatients. Individual tetramer precursor frequencies are shown below for patients in (**b**). **e**,

It is made available under a CC-BY-NC-ND 4.0 International license .

919 Concatenated FACS plots of TAME-enriched class II-tetramer⁺ cells gated on CD4⁺ T cells 920 from H3N2-infected patients. **f**, Precursor frequencies of tetramer⁺ cells from Flu+ and Flu-921 patients at acute (V1, V2, V3 or V4) and follow-up timepoints. g, Representative overlay FACS 922 plots of activation markers expressed on TAME-enriched tetramer⁺ cells compared to their 923 unenriched parent population. **h**, Frequency of A2- $M1^+CD8^+$ T cells from individual Flu+ and 924 Flu- patients expressing different combinations of activation markers PD-1, CD38, HLA-DR 925 and CD71, where CD71 was replaced by Ki-67 in the staining panel for Flu- patients. i, Overall 926 activation status of TAME-enriched tetramer⁺ cells compared to their unenriched parent 927 population of $CD4^+$ or $CD8^+$ T cells in Flu+ patients. j, T cell differentiation phenotype of 928 TAME-enriched tetramer⁺ cells in relation to the unenriched parent population of $CD4^+$ or $CD8^+$ 929 T cells. i,j, Mean and SD are shown for all acute and follow-up timepoints, except for the acute 930 tetramer⁺CD4⁺ group (n=2), which were plotted individually. Statistical significance (p<0.05) 931 was determined using Tukey's multiple comparison test for (i) number of activation markers 932 present (0, 1 or 2+) and (j) T cell differentiation subsets.

933

934 Fig. 6. Analyses of immune responses and clinical and genetic host factors. a,b, 935 Unsupervised heatmaps of immune, clinical and genetic parameters in Flu+ patients at **a**, acute 936 and **b**, convalescent timepoints. Interactive heatmaps (.html) are shown in **Supplementary Fig.** 937 8a-e for Flu+, Flu- and combined datasets. Regions of low (maroon) and high (pink) cytokine 938 clusters are boxed. c, Box plots of IFN- γ -producing cells following influenza virus infection 939 assay, at the earliest acute (V1) and convalescent (Fup) timepoints as a function of patients' 940 disease severity via binned SOFA scores of 0-1 versus 2-6. Median, IQR and whiskers 941 extending to the largest or smallest values no further than 1.5 times the IQR are shown. 942 Nonparametric Wilcoxon rank sum test with continuity correction was used for comparisons 943 between SOFA categories. Wilcoxon signed rank test (a paired test) was used to compare 944 differences between V1 and Fup among the same individuals. Tests were carried out on the 945 actual data, although plots were on a log10+1 scale for ease of visualization.



Figure 1 Nguyen et al.



Figure 2 Nguyen et al.



Figure 3 Nguyen et al.



Figure 4 Nguyen et al.



Figure 5 Nguyen et al.



Figure 6 Nguyen et al.